RTT NewsFDA Rejects Loxapine for ApprovalMedscapeMay 5, 2012 — The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) saying that the new drug application for loxapine inhalation powder (Adasuve, Alexza Pharmaceuticals, Inc) is not ready for approval in its current .
Benzinga's Microcap Movers for Friday May 4, 2012 - Benzinga
Benzinga's Microcap Movers for Friday May 4, 2012BenzingaAlexza Pharmaceuticals announced Thursday that it had received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.
Biotech Industry Hotbed of Merger & Acquisition Speculation - MarketWatch (press release)
Biotech Industry Hotbed of Merger & Acquisition SpeculationMarketWatch (press release)The company recently received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its New Drug Application for ADASUVE (loxapine) inhalation powder.
Alexza Reports 2012 First Quarter Financial Results and Provides Business Update - MarketWatch (press release)
Alexza Reports 2012 First Quarter Financial Results and Provides Business UpdateMarketWatch (press release).